AstraZeneca–HUTCHMED FDA Filing | Lucid Diligence Brief
This Lucid Diligence Brief explores AstraZeneca’s ORPATHYS and TAGRISSO FDA…
EADV 2026 Preview: Emerging Dermatology Therapies and Competitive Trends
EADV 2026 at a glance At 2026,will differentiation in dermatology move beyond…
Insulinova Partners with Ospedale San Raffaele | Lucid Diligence Brief
Avaí Bio and Insulinova Test Encapsulated Beta Cells With San Raffaele as…
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Genprex and Roche Diagnostics begin TROP2 assay validation to support…
Massive Bio and GELL Partnership | Lucid Diligence Brief
Massive Bio and GELL have launched a strategic partnership to expand AI-enabled…
Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief
Excalipoint Therapeutics and DP Technology have partnered to develop an agentic…
Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
Vedana Therapeutics Advances Migraine Antibody Pipeline | Lucid Diligence Brief
Vedana Therapeutics has emerged from stealth with $46 million in Series A…